Brian Coe, MBA ’99

Brian Coe, MBA ’99

CEO, Belay Diagnostics


Brian Coe began his entrepreneurial career in 1995 as co-founder and CEO of Litholink Corporation, a CLIA laboratory with integrated clinical decision support software that grew to serve approximately 25% of the US urology market and 10% of the nephrology market with national payer coverage before its acquisition by LabCorp in 2006. At LabCorp (NYSE: LH), Brian was promoted to Senior Vice President and led the expansion of the programs to other diseases that eventually included chronic kidney disease, cardiovascular disease, bone disease, coagulation disorders, and diabetes as the platform fully integrated into the broader organization. Litholink’s programs currently serve ~9MM pts/yr.

Brian left LabCorp to serve as co-founder and CEO of Talis Biomedical (NASDAQ:TLIS) (FKA SlipChip), a point-of-care molecular diagnostics platform for infectious disease. He led the company from conception through its IPO, led by JPM and BAML, raising approximately $500MM in equity capital over 9 years, with an additional $50MM in non-dilutive grant funding. Brian currently serves as an adjunct professor at Chicago Booth, where he previously co-created and taught Entrepreneurial Discovery course with Prof Mark Tebbe, instructs the I-Corps course at the Polsky Center, and serves as an active advisor in multiple life science start-up companies.

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.